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Abstract
We present the diagnostic and therapeutic difficulties encountered in a patient with a clinically advanced pancreatic neuroendocrine 
tumour. The report concerns a 60-year-old female patient with the diagnosis of non-functioning pancreatic neuroendocrine tumour (NET 
G1) with liver, peripancreatic lymph node and mediastinal metastases. Due to the presence of advanced disease (inoperable pancreatic 
tumour, presence of multiple metastases) the patient was considered ineligible for surgical treatment on two occasions. Tissue samples 
for histopathology were collected during an exploratory laparotomy, which made it possible to establish the diagnosis. As somatostatin 
receptor scintigraphy was positive, the patient was started on somatostatin analogues and radionuclide therapy was initiated, resulting in 
satisfactory response in the form of complete remission of liver metastases and the decreased size of the primary tumour in the pancreas.
The use of somatostatin analogues in the case of an inoperable neuroendocrine tumour which was assessed as clinically advanced, yet 
possessing a low proliferative potential, is a promising therapeutic option. (Pol J Endocrinol 2012; 63 (1): 59–64)
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Streszczenie
W pracy przedstawiono trudności diagnostyczno-terapeutyczne u pacjentki z zaawansowanym klinicznie nowotworem neuroendokryn-
nym trzustki. Opisano przypadek 60-letniej chorej z rozpoznanym nieczynnym hormonalnie nowotworem neuroendokrynnym trzustki 
(NET G1), z przerzutami do wątroby i węzłów chłonnych okołotrzustkowych i śródpiersia. Ze względu na zaawansowanie choroby 
(nieresekcyjny guz trzustki, obecność licznych przerzutów) chorą zdyskwalifikowano 2-krotnie z leczenia operacyjnego. Podczas lapa-
rotomii zwiadowczej pobrano materiał do badania histologicznego, co pozwoliło na ustalenie rozpoznania. W scyntygrafii receptorowej 
potwierdzono obecność receptorów somatostatynowych, włączono leczenie analogami somatostatyny oraz zastosowano leczenie radio-
izotopowe. W wyniku zastosowanej terapii uzyskano zadowalający efekt w postaci całkowitej regresji zmian przerzutowych w wątrobie 
oraz zmniejszenia wymiarów guza trzustki.
Zastosowanie analogów somatostatyny w przypadku nieoperacyjnego, zaawansowanego klinicznie, jednak o niskim potencjale prolife-
racyjnym, nowotworu neuroendokrynnego trzustki, stanowi obiecującą opcję terapeutyczną. (Endokrynol Pol 2012; 63 (1): 59–64)
Słowa kluczowe: nowotwór neuroendokrynny trzustki, analog somatostatyny, leczenie radioizotopowe
Introduction
Non-functioning pancreatic neuroendocrine neoplasms 
(NF-PNENs) account for 60–80% of all pancreatic 
neuroendocrine neoplasms, while the latter make up 
2–10% of all pancreatic tumours [1–3]. According to the 
latest World Health Organisation (WHO) classification, 
adopted in 2010, the following groups of neuroendo-
crine tumours in terms of grading are distinguished:
 — Neuroendocrine tumour G1 (NET G1);
 — Neuroendocrine tumour G2 (NET G2);
 — Neuroendocrine carcinoma (NEC);
 — Mixed adenoneuroendocrine carcinoma (MANEC) [4].
The manifestations of neuroendocrine tumours de-
velop late and are associated with locally advanced disease, 
which is usually already quite considerable, and with dis-
tant metastases. The primary tumour is most commonly 
located in the head of the pancreas and is large (> 50 mm). 
The incidence peaks in the fifth decade of life and both 
sexes are equally affected [3]. The usual symptoms include 
abdominal pain, weight loss, loss of appetite, nausea, and 
vomiting [3, 5, 6]. Due to the heterogenic nature of the 
tumour, and the generally considerable advancement of 
the disease process at diagnosis, the decisions regarding 
the diagnostic evaluation and optimal treatment require 
extensive experience and collaboration between various 
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Figure 2. Abdominal computed tomography (CT) scan: liver 
metastases (with the greatest mass measuring 23 mm in diameter)
Rycina 2. Tomografia komputerowa (CT) jamy brzusznej: 
przerzuty do wątroby (maks. 23 mm)
Figure 1. Abdominal computed tomography (CT) scan: 
a pancreatic head tumour measuring 55 × 47 mm
Rycina 1. Tomografia komputerowa (CT) jamy brzusznej: 
guz głowy trzuski, wymiar 55 × 47 mm
specialists, including an endocrinologist, a gastroente-
rologist, a surgeon, an oncologist and nuclear medicine 
specialists.
Case presentation
A 60-year-old female patient with the diagnosis of 
a pancreatic neuroendocrine tumour was admitted in 
September 2008 to the Department of Endocrinology, 
Silesian Medical University, Katowice, Poland, for fur-
ther diagnostic evaluation with a view to establishing 
the optimal management.
For the previous two years, she had been experiencing 
asthaenia and epigastric pain. Gastrointestinal endoscopic 
studies (an upper GI endoscopy and a colonoscopy) car-
ried out in June 2007 revealed erosive gastroduodenitis 
with Helicobacter pylori infection. Despite eradication 
treatment, the abdominal pain persisted. An abdominal 
ultrasound performed in July 2008 revealed a tumour in 
the pancreatic head measuring 34 ¥ 24 mm and several 
masses in the liver (most probably of metastatic nature). 
An abdominal CT scan confirmed the presence of a pan-
creatic head tumour measuring 55 ¥ 47 mm (Figure 1) 
and six metastatic masses in the liver (with the largest one 
measuring 23 mm in diameter) (Figure 2).
The patient was referred to the Department of 
Surgery and underwent an exploratory laparotomy 
which revealed an inoperable pancreatic tumour, and 
during which tissue samples for histopathology were 
collected from the metastatic masses in the liver and the 
peripancreatic lymph nodes. 
The histopathologic examination revealed well-dif-
ferentiated neuroendocrine neoplasm of the pancreas 
with metastatic spread to the liver and lymph nodes 
(chromogranin(+), synaptophysin(+), proliferation 
index Ki67 1%.
In September 2008, during hospitalisation at the 
Department of Endocrinology, the concentrations of 
neuroendocrine tumour markers were within reference 
ranges: 5.9 ng/24 h and 2.83 ng/24 h for 5-hydroxyin-
doleacetic acid (5-HIAA) in two 24-hour urine collections, 
respectively (reference range: 2–6 ng/24 h); 31.66 U/l for 
chromogranin A (reference range: 2–18 IU/l); 46.0 µIU/l for 
gastrin (reference range: 28–185 µIU/l) and 137.4 ng/ml for 
serotonin (reference range: 40–400 ng/ml). Other hormone 
assessments were also performed, which ruled out multi-
ple endocrine neoplasia type 1 (MEN 1). A chest CT scan 
revealed multiple subpleural nodules in both lungs and 
mediastinal lymph nodes of borderline sizes. 
A decision against performing biopsies of these 
lesions was made due to the presence of numerous 
emphysematous bullae. The patient refused to undergo 
a mediastinoscopy. Somatostatin receptor scintigraphy 
(SRS) using 99mTc-Tectrotide revealed pathological ac-
cumulation of the tracer in the head of the pancreas and 
in five masses in the liver. No expression of somatostatin 
receptors (SSTRs) was demonstrated in the nodules 
identified in the lungs. Based on the confirmation of 
the presence of SSTRs in the pancreatic tumour and 
in the liver, the patient was started on a long-acting 
somatostatin analogue, Somatuline Autogel 90 mg every 
28 days, in September 2008. 
After three doses of the drug, the abdominal symp-
toms decreased and the follow-up CT scan in January 
2009 revealed no changes in the pulmonary nodules and 
mediastinal lymph nodes, and a considerable regression 
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Figure 3. Hybrid imaging positron emission tomography with computed tomography using 68Ga-DOTATATE (68Ga-DOTA-TATE PET/CT): 
43 × 32 mm an extensive tumourous mass with calcificationthe in the head of the pancreas, with overexpression of somatostatin receptors
Rycina 3. Badanie pozytonowej tomografii emisyjnej z wykorzystaniem analogów somatostatyny znakowanych galem 68 (68Ga-
-DOTATATE PET/CT): głowa trzustki — rozległa zmiana guzowata ze zwapnieniem o wymiarach 43 × 32 mm ze zwiększoną ekspresją 
receptorów
Figure 4. Hybrid imaging positron emission tomography with computed tomography using 68Ga-DOTATATE (68Ga-DOTA-TATE PET/CT): 
the liver — a lots of liver metastases showing overexpression of somatostatin receptors
Rycina 4. Badanie pozytonowej tomografii emisyjnej z wykorzystaniem analogów somatostatyny znakowanych galem 68 
(68Ga-DOTATATE PET/CT): wątroba — liczne ogniska ze zwiększoną ekspresją receptorową w wątrobie
of the pancreatic head tumour (30 mm in diameter) with 
the presence of radiologic atrophic changes and only 
two metastatic masses in the liver. Serum concentrations 
of neuroendocrine tumour markers were still within 
reference ranges. The patient was given a recommen-
dation to continue treatment with Somatuline Autogel 
at the dose of 120 mg. 
Following the next three doses, in March 2009, a fol-
low-up abdominal ultrasound scan revealed a decrease in 
the number and sizes of the liver metastases and in the size 
of the pancreatic head tumour. The patient’s performance 
status remained good and her only complaints were hot 
flushes. There was only a slight increase in 5-HIAA levels 
in 24-hour urine collection accompanied by normal levels 
of CgA and serotonin. Treatment with the long-acting 
somatostatin analogue was continued, and in August 2009 
the patient underwent a positron emission tomography 
(PET) scan using somatostatin analogues labelled with gal-
lium-68 (68Ga-DOTA-TATE PET/CT), which makes it pos-
sible to assess the primary (Figure 3) and metastatic masses 
(Figure 4), particularly in the case of well-differentiated 
neuroendocrine tumours [7–9].
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Figure 5. Hybrid imaging positron emission tomography with computed tomography using 68Ga-DOTATATE (68Ga-DOTA-TATE 
PET/CT): the head of the pancreas — an extensive tumourous mass with calcification of the same sizes as in the previous scan, with 
overexpression of somatostatin receptors
Rycina 5. Badanie pozytonowej tomografii emisyjnej z wykorzystaniem analogów somatostatyny znakowanych galem 68 (68Ga-
-DOTATATE PET/CT): głowa trzustki — rozległa zmiana guzowata ze zwapnieniem o wymiarach jak poprzednio, ze zwiększoną 
ekspresją receptorów 
Figure 6. Hybrid imaging positron emission tomography with computed tomography using 68Ga-DOTATATE (68Ga-DOTA-TATE 
PET/CT): the liver — a lots of liver mestastees showing overexpression of somatostatin receptors, with the largest one in segment 5/8
Rycina 6. Badanie pozytonowej tomografii emisyjnej z wykorzystaniem analogów somatostatyny znakowanych galem 68 (68Ga-
-DOTATATE PET/CT): wątroba — liczne ogniska ze zwiększoną ekspresją receptorową w wątrobie, największe w segmencie 5/8
The scans performed at the Department of Nu-
clear Medicine revealed areas of somatostatin recep-
tor overexpression within the pancreatic head mass, 
liver masses and the right superior paratracheal lymph 
nodes. Given the disseminated nature of the disease and 
good expression of somatostatin receptors, the patient 
was referred for radionuclide therapy with radiolabelled 
somatostatin analogues.
During the repeat surgical consultation, the patient 
was again considered ineligible for surgery. The pa-
tient’s condition was stable and she complained of occa-
sional hot flushes and epigastric symptoms. No increase 
in neuroendocrine tumour markers was observed. The 
patient continued treatment with the somatostatin 
analogue, Somatuline Autogel, at the dose of 120 mg 
every 28 days. A subsequent 68Ga-DOTA-TATE PET/CT 
scan performed in February 2010 did not reveal any 
new masses that would exhibit somatostatin receptor 
overexpression (Figures 5, 6). 
The patient was considered eligible for radionuclide 
therapy and received four cycles of 90Y-DOTA-TATE 
between April and August 2010 and one cycle of 
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177Lu-DOTA-TATE. The complications of the radio-
nuclide therapy included secondary pancytopenia. 
The follow-up imaging studies (abdominal CT and 
somatostatin receptor scintigraphy) performed after 
completion of the radionuclide therapy showed satis-
factory response in the form of complete remission of 
liver metastases and the decreased size of the primary 
tumour in the pancreas. For the third time, surgery is 
now being considered, provided that the patient’s blood 
counts return to normal.
Discussion
The outcomes of treatment of pancreatic neuroendo-
crine tumours largely depend on the stage of the disease 
at diagnosis. In order to determine the location and size 
of the primary tumour, and to detect metastases, imag-
ing studies need to be performed [10]. 
The imaging modalities include computed to-
mography, magnetic resonance imaging, ultrasound, 
somatostatin receptor scintigraphy and PET/CT using 
somatostatin analogues labelled with gallium-68 [11]. 
The use of modern diagnostic methods, particularly 
endoscopic ultrasound (EUS), considerably improves 
the chances of early detection. The sensitivity of the 
method is 90–100% for tumours located in the head 
and body of the pancreas, and 75–80% for peripheral 
tumours. A normal picture of the pancreas in EUS practi-
cally rules out the presence of a tumour. The diagnosis of 
the disease is based on histopathology results. A biopsy 
during an EUS scan is performed if the tumour renders 
the patient ineligible for surgery. The sensitivity and 
specificity of EUS combined with a biopsy, as far as the 
diagnosis of neuroendocrine tumours is concerned, are 
84% and 92.5%, respectively [3, 12]. 
Pancreatic neuroendocrine tumours are generally 
detected late (which was the case with our patient), 
often at a very advanced stage (T2N1M1), despite the 
well-differentiation of the tumour and a low prolifera-
tion index (neuroendocrine tumour G1 [NET G1] ac-
cording to the WHO classification adopted in 2010). In 
our patient, the imaging studies (ultrasound, CT) of the 
abdominal cavity revealed a tumour in the head of the 
pancreas and liver metastases. The patient was being 
considered for surgery with a diagnosis of suspected 
adenocarcinoma of the pancreas, but the tumour was 
considered unresectable having taken into account the 
disseminated nature of the disease. The correct diagno-
sis, one of a neuroendocrine tumour, was established 
later, based on a histopathologic examination of tissue 
samples collected during an exploratory laparotomy.
Radical resection of the primary tumour, if pos-
sible — is the mainstay of treatment in pancreatic 
neuroendocrine tumours. The location and stage 
of the tumour determine the type and extent of the 
surgical tumour resection [13]. In tumours which 
are located in the head of the pancreas and which 
measure more than 3 cm in diameter, resection of 
the neighbouring organs is also recommended. If 
liver metastases are present, which is the case in 
59–80% of patients at diagnosis, a synchronous or 
metachronous resection of the primary tumour and 
the metastatic masses is recommended. Aggressive 
surgical treatment increases five-year survival rates in 
these patients from 46% to 63% (or, according to other 
authors, to 83%). In specialised liver surgery centres, 
it is possible to combine different techniques, such as 
resection of metastatic masses, ablation, embolisation 
or chemoembolisation of hepatic arteries [4, 13–16].
In the case of our patient, two national reference 
centres for surgery determined inoperability of the 
lesions due to the presence of advanced disease (unre-
sectable pancreatic tumour, multiple liver and lymph 
node metastases, suspected lung metastases) and the 
involvement of the portal circulation. During the ex-
plorative laparotomy, tissue samples from the masses 
located in the liver and the surrounding lymph nodes 
were collected, which made it possible to correct the 
previous misdiagnosis. A decision was then made 
to initiate treatment with a long-acting somatostatin 
analogue, which shows antiproliferative properties 
(though not yet proved in randomised studies on the 
pancreas), cytotoxic and cytostatic properties, leading 
to stabilisation of tumour growth [17].
Exerting direct effects through somatostatin recep-
tors [18] and indirect effects by suppressing the activity 
of growth factors, suppressing angiogenesis and exert-
ing immunomodulatory action, results in a stabilising 
effect on tumour growth and limits the development of 
metastases. Stabilisation of the disease can be achieved 
in 24–57% of patients. Studies also show that tumour 
regression can also be achieved in a small percentage 
of patients (3–9%) [3, 19, 20, 21].
Several months of treatment with the somatostatin 
analogue gave a very satisfactory result: a decrease in 
the primary tumour size and a decrease in the number 
and sizes of the liver metastases. Given the overexpres-
sion of somatostatin receptor in the tumour, confirmed 
by scintigraphy, the patient received radionuclide 
therapy with radiolabelled somatostatin analogues 
on top of somatostatin treatment. Remissions follow-
ing this treatment are confirmed by clinical studies of 
90Y-DOTA-TOC, 177Lu-DOTA-TATE, 90Y-DOTA-TATE, 
which showed that this treatment was able to reduce 
tumour mass and bring about stabilisation of the disease 
[3, 17, 19, 22–24].
In the case of our patient, non-surgical treatments 
resulted in a marked clinical improvement, regression 
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of the disease accompanied by a decrease in pancre-
atic tumour mass, and a complete remission of liver 
metastases. 
In conclusion, the use of somatostatin analogues in 
an unresectable, clinically advanced neuroendocrine 
tumour, yet exhibiting a low proliferative potential, is 
a promising therapeutic option.
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